Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 9Gastrointestinal 9Tumor-Agnostic 8Genitourinary 3Other solid neoplasm 2Dermatologic 2Breast 2Sarcoma 1Gynecologic 1

Conditions

Solid Tumors 2

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × ARQ 197 × Other solid neoplasm × Clear all
NCT01149720 2019-02-12

Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

Daiichi Sankyo

Phase 1 Completed
24 enrolled
Other solid neoplasm

Solid Tumors

NCT01699061 2019-02-12

Effect of Tivantinib on the QTC Interval in Cancer Subjects

Daiichi Sankyo

Phase 1 Completed
38 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡